HLB blood test (Heitan-LaGarde-Bradford)
The Heitan – LaGarde – Bradford blood test whose theory originates in the United States, was known as the H.L.B. blood test. The test was further developed and improved by the German doctor Heitan, who worked in Paris and died in 1977. Dr. LaGarde is a student of Dr. Heitan. In collaboration with many European doctors, Heitan and LaGarde attempted to detect cancer and graphically depict it. Dr. Bradford from the Bradford Research Institute is an American engineer, was the first to explain the biological reasons for the structural changes in coagulated blood with the test.
The two most important processes in this context are the different clot-forming processes and the pathological production of many kinds of bile salts that jointly anatomize the structure of the red blood cells, induce color changes, and destroy the fibrin network. The simple test can be performed in several minutes by a doctor or therapist. The test distinguishes between cancer and other benign or pathological conditions.
The test is not supposed to detect the initial stage of cancer in its earliest form, which is why a confusing the interpretations with other pathological circumstances is possible. In the test coagulated drops of the patient’s blood are examined under a phase contrast microscope. The microscope shows multiple aspects of the drop of blood: the fibrin network, the characteristic transparent parts, and the color changes.
The blood of the cancer patient differs from normal blood in the following areas:
- The fibrin network is partially or completely destroyed.
- The cell membrane is eroded and looks jagged.
- In the center of the drop of blood glue-like masses appear that are surrounded by transparent parts or “holes” of various sizes. Within these parts smaller bodies with other forms are recognizable.
Hormone stimulants and coagulants change the test results to an unknown, but always disadvantageous, degree. Likewise, all bodily trauma, such as operation, fractures, or heavy bleeding, also change the test results. The test is also age-dependent. With younger people the manifestations are less clear than they are with older people. In the blood of a cancer patient the open places are colored yellow or green, particularly around the edges of the transparent masses.